Caribou Biosciences is a health care company that develops and markets bio-based products, including therapeutic bioproduction solutions and agricultural biotechnology products, with a global reach and focus on innovation.

Caribou Biosciences Inc. is at a critical juncture, with its innovative CRISPR technology holding promise but its financial metrics and market performance raising concerns about its ability to sustain growth.

Caribou Biosciences, a CRISPR genome-editing company, will participate in the BofA Securities 2025 Health Care Conference, highlighting its commitment to advancing its pipeline and engaging with investors.